Changes in serum urate concentrations.
| All Patients | Patients with eGFR < 50 ml/min/1.73 m2 | |||||||
|---|---|---|---|---|---|---|---|---|
| All, n = 57 | Probenecid Monotherapy, n = 30 | Combination Therapy, n = 27 | p* | All, n = 15 | Probenecid Monotherapy, n = 9 | Combination Therapy, n = 6 | p* | |
| Final serum urate, mmol/l, mean (SD) | 0.39 (0.09) | 0.41 (0.09) | 0.38 (0.10) | 0.24 | 0.39 (0.09) | 0.42 (0.08) | 0.34 (0.05) | 0.06 |
| No. (%) achieving target serum urate < 0.36 mmol/l | 20 (35) | 10 (33) | 10 (37) | 0.77 | 5 (33) | 2 (22) | 3 (50) | 0.3 |
| Mean change in serum urate from baseline, mmol/l (SD) | 0.21 (0.11) | 0.17 (0.11) | 0.25 (0.10) | 0.004 | 0.18 (0.11) | 0.16 (0.13) | 0.22 (0.08) | 0.38 |
| Mean percentage change in serum urate from baseline (SD) | 33.7 (16.6) | 28.6 (17.1) | 39.3 (14.4) | 0.01 | 30.9 (16.6) | 26.1 (18.0) | 38.1 (12.6) | 0.18 |
| Mean change in serum urate from allopurinol monotherapy, mmol/l, (SD) | NA | NA | 0.12 (0.10) | — | NA | NA | 0.11 (0.10) | — |
| Mean percentage change in serum urate from allopurinol monotherapy (SD) | NA | NA | 23.8 (16.4) | — | NA | NA | 23.0 (15.8) | — |
↵* Probenecid monotherapy vs combination therapy. eGFR: estimated glomerular filtration rate.